Using gold nanoparticles to enhance radiotherapy for triple negative breast cancer
siRNA-based Gold Nanoparticles as a Therapeutic Enhancer for Triple Negative Breast Cancer (TNBC) Radiotherapy
This study is looking at how tiny gold particles can make radiation treatment work better for people with triple negative breast cancer by boosting the immune system's ability to fight the cancer.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health System NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-10885205 on NIH RePORTER |
What this research studies
This research investigates how gold nanoparticles can improve the effectiveness of radiotherapy for patients with triple negative breast cancer (TNBC). The approach focuses on overcoming the immunosuppressive effects of radiation therapy, which can hinder its benefits. By utilizing gold nanoparticles as radiosensitizers, the study aims to enhance the immune response against tumors and improve patient outcomes. The research will explore the combination of radiotherapy and immunotherapy to potentially increase the survival rates of TNBC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are undergoing or considering radiotherapy.
Not a fit: Patients with non-breast cancers or those who do not have triple negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple negative breast cancer, improving their chances of survival.
How similar studies have performed: Previous research has shown promise in using nanoparticles to enhance cancer therapies, indicating potential success for this novel approach.
Where this research is happening
Detroit, United States
- Henry Ford Health System — Detroit, United States (Active)
Researchers
- Principal investigator: Janic, Branislava — Henry Ford Health System
- Study coordinator: Janic, Branislava
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.